Hacking Biology - New Member Developing a Longevity Biohacking Plan & Platform

#1

I noticed we have a new member that joined a few days ago. He goes by @Hackingbiology.com , based in Europe, his name is “Fabio” and he’s getting serious about longevity biohacking and in the process of developing his plan and a software platform.

I like the way he’s approaching the effort; very methodically and thoughtfully. He sounds like he is a software engineer by training. He’s identified many of the same issues we’ve discussed here… the difficulty of tracking outcomes across multiple people of different interventions and people, data collection and management. I think he’s aligned with many of us here, wanting better outcomes tracking and data collection, and more rigorous evaluation of longevity interventions … and wanting “open source” approaches where everyone can learn from each other.

He has created a presentation on his approach, which he’s shared on google docs here: Hacking Biology - Project Presentation - Google Slides

He has a rough google spreadsheet where he’s identified possible targets for use: Protocol Planning - Google Sheets

He shared this with me:

I am in the year of buildup of my anti-aging protocol, as a hacker in the learning phase, and my understanding (other than my need), is that in the ecosystem most of the people:

  • don’t do proper measurement and related data management
  • don’t stick a documented protocol of what they are doing making difficult / impossible to compare

Most of all, there’s no collaborative system that would make it easier to start a protocol and report results, resulting in “a kind of crowd-sourced trial” (my biology researcher friends hate me, when I say so, not becoming a scientifically diligent and reproducible protocol, enabling anyone to pickup what they wish to do, but i think could be useful investigative lead).

So we need a bunch of software, knowledge base and easy pdf to print for the measurement to make it accessible, as here the learning curve and adoption is pretty high, it must be made accessible.

Said so, i am a tech entrepreneur and hacker, social committed to opensource and open data, while busy with many stuff i allocated 50k to this project development and with the goal (first towards myself) to ensure a non-commercial, collaborative and opensource hacker lead biohacking project on longevity.

His Website:

It is still pretty minimal, but provides a look at his approach and considerations so far:

13 Likes
#2

What would be the difference with @ConquerAging Michael Lustgarten @Hackingbiology.com? Anything you’re doing better, or hope to improve on your approach? Michael is mostly only altering diet and exercise because it’s low risk according to him, and altering it based on average biomarkers between each blood test correlated with diet and exercise, etc. (https://www.youtube.com/@conqueragingordietrying1797/videos)

#3

Update on the HB Project, making up cleaned-up data model and my roadmap of acquisition:

This sheet is operationally providing the required data-model elaboration for:

  • Defining the drugs/supplements with short summary of why
  • Defining how many pills each day of which product
  • Normalizing the effective acquisition (because there’s some multiple pills containing same ingredients)
  • Making the scheduling (morning / lunch / dinner)
  • Listing the supply sources / product (from a european/italian perspective)

I’m now running 40-50 pills a day, targeting some 80-90 to then trying to optimize the pills numbers (spoke to few galenic pharmacies to have custom-made pills).

Once this sheet will be completed, it’s ready for INPUT implementation of the software.

So i will move to the data model for measurement, defined as OUTPUT.

In the meantime engaging a consultant to define specifications for non-pills threatment:

  • HBOT protocol (in order to enable anyone to ideally enjoy same aviv-clinics.com telemere increasing HBOT protocol down to the local HBOT center HBOT Protocol for aging – Hacking Biology )
  • Plasmapheresis protocol with saline-albumine replacement, but while doing also blood extraction for blood sampling

All in all, i have a strong fobia of puncture needle, but for that project i’m challenging it.

We need a lot of data.

Thank you for the post @RapAdmin i will keep the project updates on this thread.

Fabio

3 Likes
#4

Targeting aging and youthful states isn’t enough, but all of the diseases states that are not caused by aging like cardiovascular disease (which also is the primary cause of death). I wrote about apolipoprotein B (ApoB) marker and why it’s so important for cardiovascular disease prevention here: Apolipoprotein B (ApoB)

Otherwise you end up in youthful state but still succumb or is paralyzed by heart attacks or strokes, over time, for example. I don’t know what it is for other diseases processes but this one is most certainty very useful for CVD prevention. It might be easy for things to get out of hand and way too complicated (i.e like zooming into a fractal forever), so simplicity is probably important as well though.

2 Likes
#5

I agree and i found out a very good guidelines that plan to integrate into the entire HackingBiology protocol: Outlive by Peter Attia .

What do you think?

Fabio

2 Likes
#6

I’ll have to think about the level to target more and research it. Eugene Braunwald (95 year old cardiologist) targets getting close to 0 LDL. But it seems at least 40 mg/dl is safe and effective and more data will come for even lower levels soon, so it seems more uncertain. I’d be very happy at 30-40 mg/dl which is around the same for newborns and which we have studies on, until we have data on ultra-low LDL how low we can go (with more and newer drugs).

#7

This is a very interesting perspective i’ve not been into, i appreciated reading about Eugene Braunwald and his position on cardiovascular diseases that LDL levels accumulate damages:

image
image1430×736 42.6 KB

Sounds
How to live to 100 before developing clinical coronary artery disease: a suggestion

Basically Dr. Braunwald advise to go forward making once (or better twice) a year injection of inclisiran for PCSK9 hacking, but to do it while already old.

Do you have references related to reaching up 30-40 mg/dl of LDL-C and this being a sustainable/healthy status?
I’d love to get into the topic, especially possibly just being a couple of injection a year, lifetime.

Fabio

1 Like
#8

Fabio, I think you’ll find the information you seek in this thread (sorry, its a long one), but generally the lipidologists like Thomas Dayspring point to the very low LDL-C levels during childhood when the body and brain are growing the most rapidly, as examples that prove that low LDL-C levels are not harmful, and are mostly likely helpful over the longer term. If your body and brain are fine with very low levels when it is needing and using nutrients at the highest rate during the person’s life, they suggest this shows that there is no harm to having low levels, and in that you certainly don’t need higher levels later in life when growth and development are minimal; thus the thinking that lower levels that lower the total AUC for lipids during your lifespan, are perhaps the best approach especially if you plan to live over 100 years.

See this thread: Cardiovascular Health

1 Like
#9

It’s sustainable, you just need to take some drugs. Inclisiran is still being studied. But you can take daily pills of for example statins, ezetimibe, bempedoic acid, and PCSK9 inhibitors monthly. Side effect profile is good for all of these, only about 10% get muscle pain from statins that disappear on drug cessation, and some rarely get elevated liver enzymes. Bempedoic acid can slightly increase risk of gout. Ezetimibe and PCSK9 inhibitors are almost side effect free. Statins and ezetimibe are generic and dirt cheap. Bempedoic acid is more expensive. PCSK9 inhibitors is much more expensive.

For lower levels we have high intensity statin trials, ezetimibe add on to statin trials, PCSK9 inhibitor trials added to statins.

Praluent (Alirocumab), this trial avoided levels below 15 mg/dL LDL by a blinded dose-adjustment strategy.

nejmoa1801174_f1
nejmoa1801174_f11500×915 130 KB

It improved outcomes:

nejmoa1801174_f2
nejmoa1801174_f21500×1131 125 KB

Side effects were equal to/better than placebo. Post-hoc analysis also showed improvement in all-cause mortality (net benefit).

https://www.nejm.org/doi/full/10.1056/NEJMoa1801174

Ezetimibe 53.7 mg/dl: https://www.nejm.org/doi/full/10.1056/NEJMoa1410489v

Repatha (Evolocumab):

nejmoa1615664_f1
nejmoa1615664_f12640×1635 200 KB

https://www.nejm.org/doi/full/10.1056/NEJMoa1615664

2 Likes